Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-31
2005-05-31
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S253090, C514S254090, C544S121000, C544S362000, C544S364000, C544S373000, C544S060000, C544S061000, C544S179000, C544S180000, C544S182000, C544S238000, C544S295000, C544S357000, C544S366000, C544S367000, C544S368000, C544S369000, C544S370000, C544S371000
Reexamination Certificate
active
06900206
ABSTRACT:
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.wherein:Z isQ is selected from the group consisting of:—W— is— represents a carbon-carbon bond or does not exist; andA is NR13R14.
REFERENCES:
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6573262 (2003-06-01), Wallace et al.
patent: 2003/0162970 (2003-08-01), Mavunkel et al.
patent: 0530907 (1993-03-01), None
patent: WO 93/01181 (1993-01-01), None
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 02/62423 (2002-08-01), None
M. Font, et al, “Indoles and Pyridazino[4,5-b]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
D. L. Romero, et al, J. Med. Chem., 36, pp. 1505-1508, 1993.
S. D. Young, et al, “2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase,” Bioorganic & Medicinal Chemistry Letters, 5(5), pp. 491-496, 1995.
M. J. Genin, et al, “Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs,” J. Med. Chem., 39, pp. 5267-5275, 1996.
R. Silvestri, et al, Antiviral Chemistry & Chemotherapy, 9, pp. 139-148, 1998.
A. Fredenhagen, et al , “Semicochliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the FungusChrysosporium Merdarium,” Journal Of Antibiotics, 50(5), pp. 395-401, 1997.
M. Kato, et al, “New 5-HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives,” Chem. Pharm. Bull., 43(8), pp. 1351-1357, 1995.
V. Levacher, et al, “Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo [2,3-b]Pyridine Derivatives,” Tetrahedron, 47(3), pp. 429-440, 1991.
Kadow John F.
Regueiro-Ren Alicia
Xue Qiufen May
Bernhardt Emily
Bristol--Myers Squibb Company
DuBoff Samuel J.
LandOfFree
Indole, azaindole and related heterocyclic sulfonylureido... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole, azaindole and related heterocyclic sulfonylureido..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole, azaindole and related heterocyclic sulfonylureido... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3428414